Summit Therapeutics Inc. — Director's Dealing 2025

Oct 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-10-21

Reporting Person: Soni Manmeet Singh (Director, COO and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-10-21	Common Stock	A	53361	$18.74	Acquired	3073603	Direct

Footnotes

F1: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025.